Polpharma European CDMO Partner & API Manufacturer since 1951 Polpharma European CDMO Partner & API Manufacturer since 1951

X

Eribulin mesylate intermediate manufacturers and suppliers on PharmaCompass

PharmaCompass
Eribulin mesylate intermediate
Also known as: 157322-83-3, Methyl 2-((2r,4as,6s,7r,8s,8as)-7,8-bis((tert-butyldimethylsilyl)oxy)-6-((s,e)-1-((tert-butyldimethylsilyl)oxy)-3-iodoallyl)octahydropyrano[3,2-b]pyran-2-yl)acetate, Methyl 2-[(2s,3r,4s,4as,6r,8as)-3,4-bis[[tert-butyl(dimethyl)silyl]oxy]-2-[(e,1s)-1-[tert-butyl(dimethyl)silyl]oxy-3-iodoprop-2-enyl]-2,3,4,4a,6,7,8,8a-octahydropyrano[3,2-b]pyran-6-yl]acetate, Amy12387, Ac-30649, Methyl 2-((2r,4as,6s,7r,8s,8as)-7,8-bis(tert-butyldimethylsilyloxy)-6-((s,e)-1-(tert-butyldimethylsilyloxy)-3-iodoallyl)octahydropyrano[3,2-b]pyran-2-yl)acetate
Molecular Formula
C32H63IO7Si3
Molecular Weight
771.0  g/mol
InChI Key
MIEJSEPCTMXSCI-SUCSLEJPSA-N

1 2D Structure

Eribulin mesylate intermediate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
methyl 2-[(2S,3R,4S,4aS,6R,8aS)-3,4-bis[[tert-butyl(dimethyl)silyl]oxy]-2-[(E,1S)-1-[tert-butyl(dimethyl)silyl]oxy-3-iodoprop-2-enyl]-2,3,4,4a,6,7,8,8a-octahydropyrano[3,2-b]pyran-6-yl]acetate
2.1.2 InChI
InChI=1S/C32H63IO7Si3/c1-30(2,3)41(11,12)38-24(19-20-33)27-29(40-43(15,16)32(7,8)9)28(39-42(13,14)31(4,5)6)26-23(37-27)18-17-22(36-26)21-25(34)35-10/h19-20,22-24,26-29H,17-18,21H2,1-16H3/b20-19+/t22-,23+,24+,26+,27+,28+,29-/m1/s1
2.1.3 InChI Key
MIEJSEPCTMXSCI-SUCSLEJPSA-N
2.1.4 Canonical SMILES
CC(C)(C)[Si](C)(C)OC1C2C(CCC(O2)CC(=O)OC)OC(C1O[Si](C)(C)C(C)(C)C)C(C=CI)O[Si](C)(C)C(C)(C)C
2.1.5 Isomeric SMILES
CC(C)(C)[Si](C)(C)O[C@H]1[C@@H]2[C@H](CC[C@@H](O2)CC(=O)OC)O[C@H]([C@H]1O[Si](C)(C)C(C)(C)C)[C@H](/C=C/I)O[Si](C)(C)C(C)(C)C
2.2 Synonyms
2.2.1 Depositor-Supplied Synonyms

1. 157322-83-3

2. Methyl 2-((2r,4as,6s,7r,8s,8as)-7,8-bis((tert-butyldimethylsilyl)oxy)-6-((s,e)-1-((tert-butyldimethylsilyl)oxy)-3-iodoallyl)octahydropyrano[3,2-b]pyran-2-yl)acetate

3. Methyl 2-[(2s,3r,4s,4as,6r,8as)-3,4-bis[[tert-butyl(dimethyl)silyl]oxy]-2-[(e,1s)-1-[tert-butyl(dimethyl)silyl]oxy-3-iodoprop-2-enyl]-2,3,4,4a,6,7,8,8a-octahydropyrano[3,2-b]pyran-6-yl]acetate

4. Amy12387

5. Ac-30649

6. Methyl 2-((2r,4as,6s,7r,8s,8as)-7,8-bis(tert-butyldimethylsilyloxy)-6-((s,e)-1-(tert-butyldimethylsilyloxy)-3-iodoallyl)octahydropyrano[3,2-b]pyran-2-yl)acetate

7. Methyl2-((2r,4as,6s,7r,8s,8as)-7,8-bis((tert-butyldimethylsilyl)oxy)-6-((s,e)-1-((tert-butyldimethylsilyl)oxy)-3-iodoallyl)octahydropyrano[3,2-b]pyran-2-yl)acetate

2.3 Create Date
2006-10-26
3 Chemical and Physical Properties
Molecular Weight 771.0 g/mol
Molecular Formula C32H63IO7Si3
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count7
Rotatable Bond Count14
Exact Mass g/mol
Monoisotopic Mass g/mol
Topological Polar Surface Area72.4
Heavy Atom Count43
Formal Charge0
Complexity966
Isotope Atom Count0
Defined Atom Stereocenter Count7
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count1
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
Flag China
Digital Content Digital Content
URL Supplier Web Content
185411-12-5
Eribulin
Shanghai Stepuppharm has a strong technical development troop and most of our technological backbone are ...
Shanghai Stepuppharm has a strong technical development troop and most of our technological backbone are Senior R&D persons and have more than 10 years experience in the Drug R&D field. Our core competitiveness is the Process development and optimization including Route design, process optimization to industrial production,of the API and their intermediate product. According to customer demand, we are able to offer the professional and integrated service of the drug process de
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY